After roughly 15 years at the helm, Dr. Kevin Tabb is preparing to hand over the keys to Beth Israel Lahey Health. The president and CEO who steered the system through a decade and a half of expansion announced on March 4, 2026, that he plans to step down within about a year. Tabb, who helped engineer the 2019 merger that created the current system, said he is not retiring right away but wants to leave while the organization is on solid financial ground. His exit comes just as the system is lining up construction on projects that could reshape cancer care in Boston.
According to the Boston Business Journal, Tabb notified the health system’s board in February and laid out a deliberate transition plan that could stretch up to a year. The Journal reports that he told trustees he does not intend to immediately take the top job at another large health system.
Beth Israel Lahey Health describes itself as an integrated system that combines academic and community hospitals, more than 4,700 physicians and roughly 39,000 employees, according to Beth Israel Lahey Health. With that kind of statewide footprint, it is not exactly a surprise that the CEO’s chair is considered one of the most influential roles in Massachusetts health care.
The system has recently been on an upswing. As reported by The Boston Globe, Beth Israel Lahey Health returned to profitability last year, posting roughly a $100 million operating gain. The Globe notes that the system has pushed a large share of care into community settings and added dozens of primary care clinicians as it shifts work away from its Boston academic medical center.
Future Cancer Hospital and Timeline
The leadership handoff is unfolding alongside one of the biggest capital projects in the city’s health sector. As detailed by Dana-Farber Cancer Institute, site preparation for a new cancer hospital is scheduled to begin in March 2026, with the total project currently projected at about $1.7 billion. Plans call for a 300-bed inpatient facility that will be connected to Beth Israel Deaconess in the Longwood Medical Area, with an anticipated opening around 2031.
Leadership Search and Regulatory Hurdles
The Globe reports that the Beth Israel Lahey Health board will conduct a national search over the next eight to ten months. Board chair Ann-Ellen Hornidge is set to co-lead the process with board vice chair Ron O'Hanley. At the same time, the system remains under a seven-year state price cap that was imposed when the 2019 merger was approved, a constraint any new CEO will have to factor into strategy.
Dana-Farber executives have been explicit about Tabb’s role in getting their collaboration off the ground. In a Dana-Farber release, CEO Dr. Benjamin L. Ebert said the partnership “would not have been possible without Kevin’s leadership,” and praised the team Tabb assembled to keep the work moving.
Hospital officials told the Boston Business Journal that the succession is meant to be steady and predictable, with Tabb remaining in the role during the search to provide continuity. For now, Beth Israel Lahey Health is attempting a relatively rare balancing act: a long-planned leadership exit on top of major construction, staffing and financial decisions that will shape the system for years to come.
